ChiCTR2400080283 版本V1.0 版本创建时间2024/01/25 09:45:49 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400080283 

最近更新日期:

Date of Last Refreshed on:

2024-01-25 09:45:11 

注册时间:

Date of Registration:

2024-01-25 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

脓毒症患者胃肠功能损伤的血清代谢组学研究

Public title:

Development of a predictive model for feeding intolerance in sepsis based on deep learning and metabolomics

注册题目简写:

English Acronym:

研究课题的正式科学名称:

脓毒症患者胃肠功能损伤的血清代谢组学研究

Scientific title:

Serum metabolomics study of gastrointestinal function impairment in patients with sepsis

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

胡琨琳 

研究负责人:

胡琨琳 

Applicant:

Kunlin Hu 

Study leader:

Kunlin Hu 

申请注册联系人电话:

Applicant telephone:

+86 151 7712 8652

研究负责人电话:

Study leader's
telephone:

+86 151 7712 8652

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

baggiowinter@163.com

研究负责人电子邮件:

Study leader's E-mail:

baggiowinter@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

广西壮族自治区人民医院 广西医学科学院

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

广西南宁市桃源路6号

研究负责人通讯地址:

广西南宁市桃源路6号

Applicant address:

6 Taoyuan Road, Nanning City,Guangxi province

Study leader's address:

6 Taoyuan Road, Nanning City,Guangxi province

申请注册联系人邮政编码:

Applicant postcode:

530012

研究负责人邮政编码:

Study leader's postcode:

530012

申请人所在单位:

广西壮族自治区人民医院

Applicant's institution:

The Guangxi Zhuang Autonomous Region People's Hospital

研究负责人所在单位:

广西壮族自治区人民医院

Affiliation of the Leader:

The Guangxi Zhuang Autonomous Region People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

KY-KJT-2023-271号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

广西壮族自治区人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of the People's Hospital of Guangxi Zhuang Autonomous Region

伦理委员会批准日期:

Date of approved by ethic committee:

2022-08-10 00:00:00

伦理委员会联系人:

易中秋

Contact Name of the ethic committee:

Zhongqiu Yi

伦理委员会联系地址:

广西南宁市桃源路6号

Contact Address of the ethic committee:

6 Taoyuan Road, Nanning City,Guangxi province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 771 218 6214

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

广西壮族自治区人民医院

Primary sponsor:

The Guangxi Zhuang Autonomous Region People's Hospital

研究实施负责(组长)单位地址:

广西南宁市桃源路6号

Primary sponsor's address:

6 Taoyuan Road, Nanning City,Guangxi province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中华人民共和国

省(直辖市):

广西壮族自治区

市(区县):

南宁市

Country:

China

Province:

the Guangxi Zhuang Autonomous Region

City:

Nanning

单位(医院):

广西壮族自治区人民医院

具体地址:

广西南宁市桃源路6号

Institution
hospital:

The Guangxi Zhuang Autonomous Region People's Hospital

Address:

6 Taoyuan Road, Nanning City,Guangxi province

经费或物资来源:

广西医学科学院

Source(s) of funding:

Guangxi Academy of Medical Sciences

研究疾病:

脓毒症  

Target disease:

sepsis

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

1)筛选脓毒症肠内营养不耐受的差异代谢物 2)基于差异代谢物和临床特征构建脓毒症肠内营养不耐受的预测模型  

Objectives of Study:

1) Screening for differential metabolites of enteral nutritional intolerance in sepsis 2) To construct a prediction model of enteral nutritional intolerance in sepsis based on differential metabolites and clinical features

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

符合脓毒症 3.0 定义及诊断标准,即存在感染且 SOFA 评分≥2 分,且可耐受肠内营养的患者。

Inclusion criteria

Patients meeting the definition and diagnostic criteria of sepsis 3.0, that is, patients with infection, SOFA score ≥2, and tolerance of enteral nutrition

排除标准:

1.年龄<18 岁或>80 岁;2.生命体征不能维持者或入院后 24 小时内死亡的患者;3.临床资料不完善的患者;4.孕妇或哺乳期患者;5.拒绝或放弃治疗者;6. 胃肠道恶性肿瘤;7.有溃疡性结肠炎、克罗恩病等肠道原发炎症的患者;8.需急诊手术者。

Exclusion criteria:

1. < 18 years old or > 80 years old; 2. Patients whose vital signs cannot be maintained or who die within 24 hours after admission Deceased patients; 3. Patients with incomplete clinical data; 4. Pregnant or lactating patients; 5. Those who refuse or give up treatment; 6. Gastrointestinal malignancy; 7. Patients with ulcerative colitis, Crohn's disease and other primary intestinal inflammation; 8. Patients who need emergency surgery.

研究实施时间:

Study execute time:

From 2022-06-01 00:00:00 To 2022-12-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2022-06-10 00:00:00 To 2022-12-10 00:00:00

干预措施:

Interventions:

组别:

脓毒症组

样本量:

30

Group:

sepsis group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

脓毒症合并AGI组

样本量:

30

Group:

AGI group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

组别:

健康对照组

样本量:

20

Group:

healthy control group

Sample size:

干预措施:

干预措施代码:

Intervention:

none

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中华人民共和国

省(直辖市):

广西壮族自治区 

市(区县):

南宁市 

Country:

China

Province:

the Guangxi Zhuang Autonomous Region

City:

Nanning

单位(医院):

广西壮族自治区人民医院 

单位级别:

三甲 

Institution
hospital:

The Guangxi Zhuang Autonomous Region People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血清代谢物

指标类型:

主要指标

Outcome:

metabolism

Type:

Primary indicator

测量时间点:

入ICU当天

测量方法:

代谢组

Measure time point of outcome:

On the day of entering the ICU

Measure method:

metabolomics

指标中文名:

白介素-6

指标类型:

次要指标

Outcome:

IL-6

Type:

Secondary indicator

测量时间点:

入ICU当天

测量方法:

ELISA法

Measure time point of outcome:

On the day of entering the ICU

Measure method:

ELISA method

指标中文名:

肠脂肪酸结合蛋白

指标类型:

次要指标

Outcome:

i-FABP

Type:

Secondary indicator

测量时间点:

入ICU当天

测量方法:

ELISA法

Measure time point of outcome:

On the day of entering the ICU

Measure method:

ELISA method

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血清

组织:

Sample Name:

serum

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

none

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

公开发表后上传至ResMan (www.medresman.org.cn)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

After public publication, upload to ResMan (www.medrescman.org.cn)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case sheet

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-01-25 09:45:11